Epidemiology of Major Depressive Disorder in Mainland China: A Systematic Review

Abstract

BackgroundMajor depressive disorder (MDD) is one of the important causes of disease burden in the general population. Given the experiencing rapid economic and social changes since the early 1990s and the internationally recognized diagnostic criteria and interview instruments across the surveys during 2001–2010 in china, the epidemiological studies on MDD got varied results. We performed this meta-analysis to investigate current, 12-month and lifetime prevalence rates of MDD in mainland China.MethodsPubMed, Embase, Chinese Biological Medical Literature database (CBM), Chinese National Knowledge Infrastructure database (CNKI), and the Chinese Wanfang and Chongqing VIP database were searched for associated studies. We estimated the overall prevalence of MDD using meta-analysis.ConclusionsSeventeen eligible studies were included. Our study showed that the overall estimation of current, 12-month and lifetime prevalence of MDD was 1.6, 2.3, 3.3%, respectively. The current prevalence was 2.0 and 1.7% in rural and urban areas, respectively; between female and male, it was 2.1 and 1.3%, respectively. In addition, the current prevalence of MDD diagnosed with SCID (Structured Clinical Interview for DSM-IV) was 1.8% and that diagnosed with CIDI (Composite International Diagnostic Interview) was 1.1%. In conclusion, our study revealed a relatively high prevalence rate in the lifetime prevalence of MDD. For current prevalence, MDD diagnosed with SCID had a higher prevalence rate than with CIDI; males showed a lower rate than females, rural residents seemed to have a greater risk of MDD than urban residents.

Microstructural brain abnormalities in medication-free patients with major depressive disorder: a systematic review and meta-analysis of diffusion tensor imaging

“…1 The disorder is the third leading cause of global disease burden, with annual total costs to society exceeding $80 billion worldwide, 2 and is predicted to be the leading health burden worldwide by 2030. 3 Numerous studies have reported cognitive dysregulation and behavioural and physical dysfunction in individuals with MDD.…”

Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: A meta-analysis

“…Generally, patients with MDD are treated with antidepressant drugs, mainly including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs); however, significant individual variability in antidepressant response has been observed in MDD patients (Cusin et al, 2002;Ferrari et al, 2013). It has been postulated that both genetic and environmental factors may have an impact on the variability of responses to antidepressant (Gu et al, 2013;Harkness et al, 2012). Many environmental factors have been identified to be associated with treatment response in MDD, such as childhood maltreatment, life stress and gender (Hong et al, 2006;Illi et al, 2009;Jankovic, 1995).…”

The Current Situation on Major Depressive Disorder in China: Research on Mechanisms and Clinical Practice

“…Using meta-analysis, Gu and colleagues revealed that the overall estimation of current, 12-month, and lifetime prevalence rates of MDD is 1.6%, 2.3%, and 3.3%, respectively; the current prevalence is 2.0% in rural areas and 1.7% in urban areas; and female prevalence is 2.1% and the male prevalence 1.3% [7]. An epidemiological study also reported that the weighted prevalence estimates for MDD in a southwestern city (Kunming) in China were 1.96% (lifetime), 1.09% (1 year), and 0.93% (1 month) [8].…”